ArticleExpert review of hematology2010
Targeted therapy of BCL6-dependent diffuse large B-cell lymphomas by heat-shock protein 90 inhibition.
Article in Expert review of hematology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 8 citations in OpenAlex.
- PU-H71 (NSC 750424): a molecular masterpiece that targets HSP90 in cancer and beyond.Frontiers in pharmacology · 2024Review
- Expanding horizons: new roles for non-canonical RNA-binding proteins in cancer.Current opinion in genetics & development · 2018Review
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heat-shock protein (HSP)90 is a molecular chaperone involved in the proper folding and cellular transportation of many signaling proteins that are deregulated in lymphoma. HSP90 inhibition results in proteasomal degradation of these proteins, leading to antitumoral activity. Recent studies have focused on the use of HSP90 inhibitors as potential therapies for non-Hodgkin lymphoma. BCL6 plays a critical role in the pathogenesis of most diffuse large B-cell lymphoma (DLBCL), the most frequent non-Hodgkin lymphoma. The current study demonstrates that HSP90 forms a complex with BCL6, and inhibition of HSP90 with the drug PU-H71 selectively kills BCL6-positive DLBCL in animal models. These data support the use of HSP90 inhibitor PU-H71 for treating patients with BCL6-positive DLBCL.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.